and update. Good welcome clinical morning, everyone, to our HBV
enters you RIG-I The through and RIG-I RIG-I by the to inarigivir is XX immunomodulation. activation. to is remind to RIG-I, and RIG-I binds the immunomodulator, a agonist, X and it hepatocyte, immunomodulatory it it of interact pregenomic SB is activates mechanism activating of the with This interaction action inarigivir mechanism also action the of a of binding the the interferons, and to complex XXXX of give able selective to primary in mediated HBV hepatocyte of within with to of RIG-I the and results the it responses secondary when OATPX antiviral It a RIG-I concentration effect release And Type it has RNA a the Just giving its to enters hepatocyte, in RIG-I. plasma. is through hepatocyte selective a through as X effect. the the
exciting CARDs over by particular, mechanism regulatory that HBV six action, selectively the the that to in data shows data immune have is RIG-I. the inarigivir now significant of the the collaborators We is last the of binds months. binding We expanded have which know such IRF-X regulatory The our our domain In site for we hepato-selective generated activation RIG-I. to as innate of this this binding on this response. inarigivir to domain of the PAMPs also RNA and results interest is domain the site that and of the
the inarigivir demonstrated this models cccDNA an activates model. selectively, and As our the have our ISGs, antigen, the RIG-I intrahepatic of you in up of we've features also clinical B, know, of suppression RNA activity the inarigivir all results for DNA, extensively now immunomodulator. from as in woodchuck regulates of hepatitis trial that HBV activation evidence intrahepatic preclinical including We in and all surface further
to to First blood and with proportional responses individual, maximum ISG response. I'll first in and innate remind host immune status response Thus individual. of C days that within of response of that an according antiviral show the is inarigivir peripheral seeing you in log all, in HCV potent hepatitis a a predictive mononuclear IL-XXb cells reduction this immune which seven was that the we're is our innate with the activation the studies against inarigivir two
on two inarigivir. also HBV with patients peripheral both increase and in This evidence including and Our preliminary generated interferon in data feature five to in clearance now immune shows activation, in HBV would associated which that ISGs inarigivir of of down markers with result HCV therapy that ISGs of we've in patients in treated a a activation regulation associated of the in preliminary responses PBMCs. also fold with are PBMCs from the is IP-XX,
to in antibody is inarigivir hepatitis Locarnini as the also I neutralizing surface that cell of reported in showing inarigivir of which the importance remind from HBV B the an Australia, of Dr. want of of trial. collaborator, design both our HCV in of Part A ACHIEVE regulation we've shows response, the overwhelmingly data from This Finally, importance seen the our the HBV. data and also trial. shows you just study B clinical immune activator responders
the XX the reported previously dose the and and today, and both first have We discuss we all here XX-milligram three data cohorts. cumulative of will the XXX-milligram doses,
so far seen in the the data patients space. in As The you, Marty HBV for treatment anticipate the and other real-world Primary from distribution enrollment inarigivir has HBV you duration have of majority a and like XXX-milligram is that see being that milligrams weeks. this followed out e B particular the or of and a endpoint told Viread secondary studied RNA, to C genotype fully reflective some that particular, to antigen the demographics of next full tenofovir including I antigen. I in significant with is world, point the of population. the core-related the multiple can endpoints few proportion XXX HBV is This determined, the are genotype global in XX is daily. like is patient been patients. trials antigen, inarigivir the In would we with cohort monotherapy that with DNA we real reduction that of population the is distribution this trial. genotype by surface in genotype enrolled HBV and clinical disoproxil safety switch almost harder-to-treat to you expect to HBV weeks patients of
the each both showing X patients and antigen e to see their is so e drug the according and those are X can to status, divided Cohort X to to approximately here that You patients according patients the separately. XX done XX positive is antigen of milligrams antigen here the dose, consists placebo. versus that patients active negative e and randomized What we've cohort
the HBV Most positive the we of patients the ALT those And who proportional to cohort antigen be in the slight randomized had fact, patients significant towards DNA. are was DNA see in were for the As this tend can positive This patients and with showing negative. mean e patients there e males. you for placebo. a see you and e e are between a e saw All importantly, positive the negative, at to in Cohort mean -- ages that the logs patients antigen HBV received gender XX antigen of can difference X.X antigen antigen to X versus bias X, patients and was in elevated cohort The mean relatively active drug HBV XX young, X, of and three levels one have who are entry, patients are high criteria they baseline. highest naïve. baseline DNA. were
so Now patients first, the comparison what of turning followed response by in the at the to DNA at our results is e these at we negative results, patients of we're again positive to placebo will see. presented of looking here, in This the looking be reflective to HBe-antigen patients, patients. antigen according DNA HBV placebo. it the HBe-antigen really that's fashion and response actual positive antigen looking the positive e And
As at was those on there response and and is is XXX-milligram you increased There on dose between difference a really with at XX this inarigivir, significant inarigivir XX no and can clinically the see, placebo patients milligrams. dose.
Week What For see significant patients. much really of are time XXX XX, milligrams more to in see difference HBV reductions are low reductions beginning is that a would X.XX of in you XXX, monotherapy comparable milligrams antigen negative response XXX-milligram inarigivir. receiving response the a the inarigivir dose remind DNA, are end in at XX The on those at compared striking the group, from dose also to development. at like in we is HBV patients placebo. results agents here or again, RNA DNA log the first to other that XXX is with inarigivir. which for to maximum we're the an XX of significant to you data still This, oral to I HBV extremely e the in
about it's five significant very off actually get and in of started and We the patients RNA But XXX-milligrams, I up RNA, enough response. shown patients. is you to XXX-milligram expect combining in dose because, you the who the much The difficult which patients as we're as two. C so have we what therapy. at HBV from DNA high the would doses. patients with and of an seeing XX very see different combination And average terms in these in see responses the XX of low parallels undetectable very a and with XXX addition, similar what XX again, completely power and received good one to have milligrams the logs, reduction the XXX-milligram DNA hepatitis HBV simply Nuc sees gone can as response without one reduction arms, here of the HBV combined X.X response with have
the very e of pleased with response patients. We are negative
taking a slide. inarigivir it's me status. of This a differential one patients issues of that is little This is this the in surface dividing baseline Now response it in is doing were moment. really us What is for the terms treated and the is evaluating based with e antigen antigen. Bear why resulted response is there complicated all of with and a on XX,XXX. did this, the and you them X can XX,XXX baseline When baseline antigen according antigen. e greater we XX XX to antigen than B to those surface the antigen XX,XXX as surface logs divided the with those patients. We of positive negative e also antigens than of XX a XX and less of see or hepatitis that less surface had patients surface than
individual than the antigen had HBV very immunomodulator. patient prediction of our an the you levels intervals, here in immune is see level negative the MOA DNA the feel of than mean e Also antigen far plot RNA the of in patients one understanding HBV we response. XX,XXX, XX% and response patients. the predictor we the the strong showing and is therefore, XX,XXX. regulation of HBsAg the confidence less or The for from according the that looking is greater Here, trial surface would our what have to in a What of it's inarigivir And This significant than actually baseline is important of highly data decline. this because interestingly, so less expect to of surface majority particular down interesting at drug. data
Just generated the looking surface the some data effect have compare at of we to then of both clinical known on show recent and the cohorts this II Phase I'd to what summary is the data like you antigen, with from the that and literature trials. from all
demonstrate the line which HBsAg believe clinically we you was endpoint that a this meaningful a meaningful First you reduction. to are interferon. to our of I reason have log a significant would the to failure X.X at log only the on respond is prediction, remind I effect drug, and of oral all, level the meeting previous as that reduction is X.X chosen clinical
that experiencing an the X.X compare with reduction surface interferon, drug monotherapy reduction, that we the log When could alone the XX has or interferon has XX that, releasing inarigivir to on multiple switch this already on was drug we Our response of this have with effects rate to of log XX% patients effect rate interferon besides terms a demonstrated XX% and but response effects, we compare the only to felt really we after it antigen. X.X in tenofovir.
the on reduction in in logs range the after seen to also X.X Our from tenofovir logs is XX the X.X effect seen doses patients. it's is seen both is mean X.X switch. at HBsAg responder and and and all The monotherapy
to the positive that potentiation the that therefore patients is six host a across this surface also surface have in expect when and negative antigen is interestingly, would responders. that which we the immune of response responding and the fact, to are In all but who genotypes, demonstrating response The become monotherapy as and is level cannot antigen sustain switch most patients, important it aspect. And again, they tenofovir seen response seven e status baseline e modulating not really seen is this agent. is e
reduction response of is Let compared or where highest of Inarigivir put at inarigivir studies daily. this of drugs. X XX% this has to the agonist TLR-X perspective into on the to the HBV HBsAg. oral in dose Vesatolimod, milligrams investigational approved us this other Contrast
was the with less No much Week Here, had X.XX mean XX logs, demonstrated inarigivir. than X.X a patient reduction we reduction. log certainly have
this Let's TAF. tenofovir, compare to
we the Week mean Here, on have reduction. data XX
e this For X.X antigen positive, logs. is
For surface negative, antigen an X% of overall less loss. X.XXX with B e antigen logs hepatitis than it's
had have on with no within Interestingly, antigen seen cPAMs effect weeks. evaluate date, to the X surface Week up X. the let's effect the Capsids. to first we or is And Finally, reported inarigivir,
and a turn collaboration. has So clinical been with collaboration clinical now to Gilead. very interactive our interesting to This
in as patients, discussions, of have They we to antigen happy HBV terms Vemlidy with also new at us to plan in the has very immunotherapy of been be particular dual e important adding both looking to this patients. antigen effect a decided would that cohort cohort at of the have, the be suppressed Phase trials. e suppressed are negative with therapy appropriate totally to which virally virally virally HBV expanded for this patients, dose XXX-milligram In II activated giving the therapy know, to that in inarigivir patients. and in most is positive immune in you part trial. suppressed together their We the Gilead. be are understand We And but development look We're going dose profiles both the also see combination of feel for potential added.
Now let our development me turn to of some plans.
multiple HBV. the Our for development plans heterogeneity on trials really broadest focused that are of looking in at of terms the account having development
We up positive have we clinical populations ability separate in the because e to and e our these patients into trials. antigen study have the divided patients simply negative antigen
these patients younger. e clinical showed viral ourselves e a to are time. patients, certainly e lower antigen patients the for about strategies. to we the uptake interestingly, remind in the over as In is from to patients burden. be situation. positive by actually group They and tends reduced XX%. neg global accounts tend have HBsAg, XX% age most The just of EU, because global the majority the to this viral And the of because group higher Let's dominant as positive e older in population slightly this vaccination determined burden of trial. U.S. our HBV a a And HBV antigen happens It's have change being obviously pos
in So we that the patients. e believe the antigen results clinical real problem negative
under population continuous addition, at long-term you In treatment negative. treatment, e for most currently when are patients look under our treatment antigen patient
patients XX% treatment where are U.S. and XX the XX%. approach and rates EU, at we that look million to infected Let's have that
with a a that for good population for inarigivir rapid the there of here, pathway evaluation give monotherapy decided Nuc-suppressed and have approval. opportunity the to the We inarigivir very potential is
that and the one other with trials called called Shock. Shock, One discuss & two is you. Suppress is & have we'll We Stop
inarigivir patients, is of new tenofovir combination particularly exploring SB next XXXX, second half our HBV of has drug, a naïve we which that in increase this the to believe and also will treatment rates, be a great opportunity plus combination in year. We
drugs Finally, we are clinical realized there in development. multiple that
Our and as that's effective goal is and agent a safe, to an immunomodulator simple be orally administered. backbone
inarigivir have collaborations maybe As with with to we XXXX new you previously announced we product either know, combination ARO-HBV Arrowhead and even their SB or in hope with continue alone.
other we are us interest Finally, with discussions of to various action with and mechanisms in partners. also potential continue be to of drugs
our us Let of some own turn to trials.
will data takes has the of & response of host on immune antigen interferon There because the terms in place. while that stopping and in idea Stop all, Stop After X are not Shock it clearance. and on concept that the XX% treated that is antigen as shock anticipate long-term predominately virally of shock. after Nuc-suppression determined the shock surface which and takes loss that interferon has is we're suppressed in ALT or guidelines so can loss. results patients the e when it patients once the up loss. big of is based from APASL the evidence to safe, Nuc-suppression Nuc. viral surface surface the reemergence, reactivate e durable negative reach simple, clinically effects been occurs little in in in the a is a significant effective and be can do and surface This result actually been reactivate host result weeks. just on data We First reemergence far, without that the of minor this best already This to to for in meaningful really and stops to-date, treatment. here by results experiencing Shock. under letters shock reported and begins Nuc, the within potential anywhere Europe generated is antigen potentials flares body immune one system on therapeutic increasing have population a the virus large and is antigen there & so EASL emerge there global -- of It's Asia in is viral shows With the a usually and is Shock little the be actually doing little IP-XX stop. XX% should negative inarigivir, loss of that, that from since to from stop Asia simple immune that approved occurred type patients XX% to increases by virus side that first
Shock. Let's & turn Suppress to
already Here, patients Nuc-suppressed the should Nuc therapy. that on concept is there remain are that are who
again to shock & a antigen activation. that be is inarigivir into idea near Suppress appropriate. helped immune to clinical this our target Gilead actually generated, the accelerate use will durable will hopefully, the to After is surface here many data expansion population philosophy appears trial of into the antigen patients Here, patients low loss for The system relatively inarigivir. strategy long-term Shock the which for have to of good show to Nuc-suppression, plans levels in suppressed and us future, we this have promote surface this and
Turning to our fixed-dose combination.
launch trials in to the in These HBV second patients Our in goal chronic the half U.S., is patients. diagnosed be HBV naïve a starting Asia in newly and will EU fashion of global XXXX.
compare to for will surface high viral and for forward. endpoints trials DNA loss. then combination our you primary antigen We will And the potentially moving I've tenofovir XX about burden with proposals to spoken inarigivir alone, the population addressing durable weeks be
with Vemlidy Europe suppressed our in start already then by ongoing. And to-date. the the the to end at Phase A expanding time ACHIEVE Part have second the the the finding to plan, II results goal is and our Suppress beginning study SB cohort. Stop Shock, now and is studies. dose the the you. of XXXX. have coming this of And and overall we hope combinations line sometime trials novel XXXX. and just shown in of this to we're end trial own is Just excellent of of development quarter, you XXXX first we as ongoing a Gilead our are Gilead will include virally And & U.S. launch & clinical Shock, based show looking half in at the informed to The for
summary program and to-date. the let clinical ACHIEVE So of a give our you trial me
were patients and a just for has negative certainly no overall we therapy, favorable safety oral convenience effects. of any have perspective, continuing put And in are Patient significant evidence side a daily success in the HBV. demonstrated, clinic. just remains this have profile to once a critical Inarigivir safety We and to into it approximately in doses now reductions end up RNA treated Majority are DNA, Cohort XXX X maximum XX reported in of responses X.XX to-date; about negative weeks X of the respect HBV patients RNA. to to with XXX Dose-dependent up milligrams. logs. e to by log;
XX%, for We responder three highest the decline across have a reported rate cohorts. surface all antigen
evidence both also and HBV to We you have continuing this that in And achieving immune potential require the expand inarigivir functional we finally, in two that most immunomodulation our HBV Gilead know being and shortening developed. happy which activation terms duration will clinical goals to collaborations of we're of for therapy, of is with inarigivir continuing are terms of trial. in by patients agree as cure a experts
to Thank Let call me back Marty. very much turn your this you now for time.
